Squamous cell carcinoma antigen and carcinoembryonic antigen levels as prognostic factors for the response of cervical carcinoma to chemotherapy

Meier, W.; Eiermann, W.; Stieber, P.; Fateh‐Moghadam, A.; Schneider, Achim; Hepp, H.

doi:10.1016/0090-8258(90)90002-3

Cited by 18 publications

(7 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An overall accordance of 84% was reported in 49 patients [47]. In patients who receive chemotherapy as a second line treatment after radiotherapy the course of SCC antigen reflects the clinical response in 87-100% of the cases [33,39,42]. However, the sensitivity of SCC antigen measurements to detect small tumor volumes remains to be established.…”

Section: Prognosismentioning

confidence: 65%

The Clinical Value of Squamous Cell Carcinoma Antigen in Cancer of the Uterine Cervix

et al. 1998

View full text Add to dashboard Cite

A review is given of the clinical use and interpretation of serum tumor marker levels during the treatment of patients with cancer of the uterine cervix. Pretreatment serum squamous cell carcinoma (SCC) antigen provides a new prognostic factor in early stage squamous cell carcinoma of the uterine cervix. Elevated serum values of SCC antigen at the time of diagnosis of stage IB and IIA cervical cancer indicate a 3 × increased risk of tumor recurrence, independent of tumor diameter, grade or the presence of lymph node metastases. High pretreatment SCC antigen levels could therefore be used to select ‘high-risk’ patients for adjuvant therapy. Measurement of the serum SCC antigen levels provides a means of monitoring the effect of therapy. During the postoperative follow-up of patients with localized cancer of the uterine cervix the measurement of SCC antigen can lead to the early detection of recurrent disease when curative therapy is still an option. The profile of serum SCC antigen parallels the response to radiotherapy and provides a way of evaluating the effectiveness of chemotherapy. Serial measurements after surgery and during radio- and chemotherapy demonstrate that SCC antigen is a more sensitive marker for recognizing tumor progression or recurrence than CYFRA-21.1, TPS or CEA. When following up patients with a pure adenocarcinoma of the cervix measurements of serum CA 125 and CEA are preferred over SCC antigen measurements.

show abstract

Section: Prognosismentioning

confidence: 65%

The Clinical Value of Squamous Cell Carcinoma Antigen in Cancer of the Uterine Cervix

et al. 1998

View full text Add to dashboard Cite

show abstract

“…With the development of a sensitive radioimmunoassay, this marker can be readily detected in the serum and is now considered a valuable tool for monitoring cervical cancer. Serum SCC-Ag levels correlate with the extent of disease [6-8], response to radiotherapy [9], response to chemotherapy [10,11], and can be used to predict survival and tumor recurrence during follow-up [12-16]. Several studies have reported the use of serial SCC-Ag data for post-therapeutic monitoring.…”

Section: Introductionmentioning

confidence: 99%

Use of serum squamous cell carcinoma antigen for follow-up monitoring of cervical cancer patients who were treated by concurrent chemoradiotherapy

et al. 2010

View full text Add to dashboard Cite

BackgroundTo investigate the significance of monitoring the levels of the serum squamous cell carcinoma antigen (SCC-Ag) for the detection of recurrent disease in patients with cervical cancer treated by concurrent chemoradiotherapy.MethodsThe records of 112 patients with cervical cancer were reviewed. Serum SCC-Ag levels were measured at regular follow-up visits. A SCC-Ag level of 2 ng/mL was considered the upper limit of normal. Biochemical failure was defined as two consecutively increasing SCC-Ag values above normal. Recurrent disease was confirmed by histologic and radiographic studies.ResultsEighteen patients (16%) developed recurrent disease. Sixteen patients had initially elevated SCC-Ag, post-treatment normalization of SCC-Ag, and tumor recurrence. The SCC-Ag difference (ΔSCC-Ag), defined as the difference between the last value after two consecutively increases above normal and the value immediately before the elevation, had good clinical performance in predicting cancer recurrence. The cutoff value of ΔSCC-Ag was 0.95 ng/mL.ConclusionsSCC-Ag is a relatively good method for the detection of disease recurrence in patients with cervical cancer who were treated by concurrent chemoradiotherapy.

show abstract

“…[17] The presence of lymph node metastases has extra stated impact on the CEA values than the primary tumor. [18] There has been a lack evidence in the literature comparing pretreatment CEA values and its correlation with lymph node metastasis. Hence this study was conducted to correlate the pretreatment CEA values and presence of lymph node metastasis in Carcinoma Cervix.…”

Section: Cea As a Tumor Marker In Predicting Pelvic And Para-aortic L...mentioning

confidence: 99%

CEA as a Tumor Marker in Predicting Pelvic and Para-aortic Lymph Node Metastasis in Squamous Cell Carcinoma Cervix

BR,

Viswanathan,

Reddy

2024

Asian Pac J Cancer Biol

View full text Add to dashboard Cite

Background: Carcinoma cervix is the major cause of death from gynecological malignancies. Isolated paraaortic lymph node metastasis detected on the initial diagnosis of cervical cancers could be addressed via extended paraaortic lymph node irradiation. Serum Carcinoembryonic antigen (CEA) is useful in detecting early Para aortic lymph node (PALN). Materials and Methods: Fifty patients of histologically proven squamous cell carcinoma of cervix have been recruited into the study. We assessed pelvic and Para aortic lymph node status via CT or MRI scans. Serum CEA ranges had been evaluated in all from stage I to IV before starting the treatment.Results: We observed that high pretreatment CEA values were associated with the pelvic and paraaortic lymph node metastasis 65.2% of the patients with high pretreatment CEA value had PALN metastasis (p=0.002). 47.8% of the patients with high CEA had pelvic lymph nodal metastasis (p=0.077) and 70% of the patients with high pretreatment CEA had both Pelvic and PALN metastasis which was statistically significant (p=0.020).Conclusion: Carcinoembryonic antigen levels should help to prognosticate the Carcinoma Cervix patients and predict the presence of Para-aortic and Pelvic lymph nodes. This may be effective tool for detecting early failures in patients with Carcinoma Cervix

show abstract

Squamous cell carcinoma antigen and carcinoembryonic antigen levels as prognostic factors for the response of cervical carcinoma to chemotherapy

Cited by 18 publications

References 15 publications

The Clinical Value of Squamous Cell Carcinoma Antigen in Cancer of the Uterine Cervix

The Clinical Value of Squamous Cell Carcinoma Antigen in Cancer of the Uterine Cervix

Use of serum squamous cell carcinoma antigen for follow-up monitoring of cervical cancer patients who were treated by concurrent chemoradiotherapy

CEA as a Tumor Marker in Predicting Pelvic and Para-aortic Lymph Node Metastasis in Squamous Cell Carcinoma Cervix

Contact Info

Product

Resources

About